Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13242721 | 1.00 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL16731191 | 0.80 | — | — | |
| SCHEMBL13243089 | 0.80 | — | — | |
| SCHEMBL16182286 | 0.77 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL880892 | 0.77 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL12931748 | 0.77 | KMT2A (0.31) | ALDH1A1 | |
| SCHEMBL27614258 | 0.77 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL880847 | 0.74 | CYP1A2 (0.33) | — | |
| SCHEMBL8101461 | 0.74 | CYP1A2 (0.33) | — | |
| SCHEMBL880849 | 0.74 | CYP1A2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2537844-A1 | Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof | Purdue Pharma L.P. (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2324013-B1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20110178090-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2011-07-21 | — | — | US | disclosed |
| WO-2010010458-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178090-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | OPRK1, OPRD1, P2RX4 | ALDH1A1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.